?Effect of febuxostat against coronavirus

The effect of febuxostat against lung injury induced by COVID-19 virus in infected patients: A clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190727044343N1

Enrollment

Registered

2020-04-05

Start date

2020-03-16

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Acetaminophen + Febuxostat. Intervention 2: Control group: Acetaminophen + Hydroxychloroquine.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients infected with COVID-19

Exclusion criteria

Exclusion criteria: Severe disease patients that need hospitalization.

Design outcomes

Primary

Measure	Time frame
CT-scan findings. Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: CT-scan.	—

Secondary

Measure	Time frame
Fever. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: Thermometer.;Lymphocyte count. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: CBC test.;CRP. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: Laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLotfollah Davoodi

Mazandaran University of Medical Sciences

lotfdavoodi@yahoo.com+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026